PolyPid Total Assets
PolyPid total assets. Based on the latest financial reports, PolyPid (PYPD) holds total assets worth $22.31 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see PYPD stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of PolyPid (2012–2025)
Total assets of PolyPid from 2012 to 2025. This chart illustrates how PolyPid's total assets have evolved over time, based on quarterly financial data. See PYPD stock price for real-time trading data and today's change.
PolyPid - Asset Composition Analysis
PolyPid Total Assets Breakdown (December 2025)
PolyPid total assets breakdown as of December 2025. PolyPid's total assets of $22.31 Million consist of 68.3% current assets and 31.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 28.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $1.11 Million | 5.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how PolyPid's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is PolyPid's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: PolyPid's current assets represent 68.3% of total assets in 2025, a decrease from 76.4% in 2012.
- Cash Position: Cash and equivalents constituted 28.7% of total assets in 2025, down from 63.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 5.0% of total assets.
PolyPid Competitors by Total Assets
Key competitors of PolyPid based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
PolyPid - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.97 | 1.31 | 14.53 |
| Quick Ratio | 1.82 | 1.31 | 14.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.49 Million | $3.89 Million | $47.44 Million |
PolyPid - Advanced Valuation Insights
This section examines the relationship between PolyPid's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.05 |
| Latest Market Cap to Assets Ratio | 3.48 |
| Asset Growth Rate (YoY) | -11.6% |
| Total Assets | $22.31 Million |
| Market Capitalization | $77.73 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values PolyPid's assets at a significant premium (3.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: PolyPid's assets decreased by 11.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for PolyPid (2012–2025)
The table below shows the annual total assets of PolyPid from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.31 Million | -11.55% |
| 2024-12-31 | $25.22 Million | +64.06% |
| 2023-12-31 | $15.37 Million | -40.81% |
| 2022-12-31 | $25.97 Million | -41.29% |
| 2021-12-31 | $44.23 Million | -41.68% |
| 2020-12-31 | $75.85 Million | +124.63% |
| 2019-12-31 | $33.77 Million | +133.12% |
| 2018-12-31 | $14.48 Million | -36.98% |
| 2017-12-31 | $22.98 Million | +19.48% |
| 2016-12-31 | $19.24 Million | +675.69% |
| 2015-12-31 | $2.48 Million | +26.60% |
| 2013-12-31 | $1.96 Million | +26.47% |
| 2012-12-31 | $1.55 Million | -- |
About PolyPid
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients unde… Read more